Research programme: purine modulators - InotekAlternative Names: INO-1271
Latest Information Update: 08 Oct 2007
At a glance
- Originator Inotek Pharmaceuticals
- Mechanism of Action Purinergic receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 08 Oct 2007 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
- 23 Jul 2007 Preclinical trials in Glaucoma in USA (unspecified route)